{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:12Z","timestamp":1794096012304,"version":"4.8.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Acute severe ulcerative colitis (ASUC) is a medical emergent condition, and approximately one-third of patients with ASUC do not respond to corticosteroid. Whether small molecule drugs are efficient and safe for salvage therapy of ASUC is not well-understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Consecutive patients with ASUC who failed responding to first-line corticosteroid were retrospectively enrolled. Clinical, laboratory, endoscopic, and pathological data were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Five Asian male patients (median age of 38.9\u00a0years old) with ASUC who received salvage therapy with upadacitinib were enrolled. The mean (\u00b1\u2009standard deviation) disease duration was 3.44 (\u00b1\u20093.30, 0.53\u2009~\u20097.88) years. Baseline Montreal disease extent, C-reactive protein, and erythrocyte sedimentation rate were four (80%) E3 and one (20%) E2 disease, 40.54 (\u00b1\u200974.26) mg\/dl, and 24.50 (\u00b1\u200919.09) mm\/h, respectively. Daily upadacitinib 45\u00a0mg was prescribed for 56\u00a0days in all patients. Clinical response, clinical remission, corticosteroid-free remission, and endoscopic improvement at weeks 8 and 12 were achieved in five (100%) and five (100%), four (80%) and five (100%), four (80%) and five (100%), and four (80%) and five (100%) patients, respectively. One (20%) patient achieved histo-endoscopic remission at week 24. None of them had re-hospitalization or colectomy during the follow-up period but one patient developed penile simplex-1 infection which resolved after topical antiviral ointment without upadacitinib discontinuation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Upadacitinib is an efficient salvage therapy for patients with ASUC. Further investigations are essential to assess long-term durability, safety profile, and viability as a bridging regimen in the treatment of ASUC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00384-025-04825-w","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:58:45Z","timestamp":1739303925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Upadacitinib as rescue therapy for corticosteroid failure acute severe ulcerative colitis: an Asian experience from Taiwan"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-4958","authenticated-orcid":false,"given":"Chen-Shuan","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-5371","authenticated-orcid":false,"given":"Puo-Hsien","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"12","key":"4825_CR1","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1097\/MIB.0b013e318292fae6","volume":"19","author":"A Windsor","year":"2013","unstructured":"Windsor A, Michetti P, Bemelman W, Ghosh S (2013) The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. Inflamm Bowel Dis 19(12):2695\u20132703","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"4825_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/apt.13670","volume":"44","author":"JH Chen","year":"2016","unstructured":"Chen JH, Andrews JM, Kariyawasam V et al (2016) Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 44(2):127\u2013144","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"4825_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L (2022) Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7(2):161\u2013170","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"4825_CR4","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","volume":"17","author":"C Steenholdt","year":"2023","unstructured":"Steenholdt C, Ovesen PD, Brynskov J, Seidelin JB (2023) Tofacitinib for acute severe ulcerative colitis: a systematic review. J Crohns Colitis 17(8):1354\u20131363","journal-title":"J Crohns Colitis"},{"issue":"9857","key":"4825_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J et al (2012) Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380(9857):1909\u20131915","journal-title":"Lancet"},{"issue":"4","key":"4825_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Lin J, Ryder TF et al (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 42(4):759\u2013773","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"4825_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME et al (2015) Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149(2):350-355.e352","journal-title":"Gastroenterology"},{"issue":"10","key":"4825_CR8","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ibd\/izad180","volume":"29","author":"CH Zinger","year":"2023","unstructured":"Zinger CH, Ringel Y, Eitan M et al (2023) Upadacitinib for acute severe ulcerative colitis. Inflamm Bowel Dis 29(10):1667\u20131669","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"4825_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/imj.16192","volume":"53","author":"A Eqbal","year":"2023","unstructured":"Eqbal A, Hilley P, Choy M, Srinivasan A, de Cruz P (2023) Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis. Intern Med J 53(8):1497\u20131500","journal-title":"Intern Med J"},{"key":"4825_CR10","first-page":"jjad115","volume":"Jul 9","author":"R Gilmore","year":"2023","unstructured":"Gilmore R, Tan L, Fernandes R, An YK, Begun J (2023) Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. J Crohns Colitis Jul 9:jjad115","journal-title":"J Crohns Colitis"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-04825-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:50:15Z","timestamp":1739346615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-04825-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4825"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-04825-w","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Review Committees of the study institutes: FEMH-107145-F and Chang Gung Medical Foundation 202400030B0. All enrolled patients provided written informed consents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}